CoChat

Increased Antifungal Drug Resistance in Clinical Isolates of Cryptococcus neoformans in Uganda

Open access
Smith, Kyle D., Achan, Beatrice, Hullsiek, Kathy Huppler, McDonald, Tami R., Okagaki, Laura H., Alhadab, Ali A., Akampurira, Andrew, Rhein, Joshua R., Meya, David B., Boulware, David R., Nielsen, Kirsten, Musubire, Abdu, Nabeta, Henry W., Williams, Darlisha A., Morawski, Bozena, Rolfes, Melissa A., Ndyetukira, Jane Francis, Ahimbisibwe, Cynthia, Kugonza, Florence, Sadiq, Alisat, Dyal, Jonathan, Neborak, Julie M., King, Alexa M., Yueh, Nathan, Velamakanni, Sruti S., Namudde, Alice, Kandole, Tadeo Kiiza, Eva Laker, Julian Kaboggoza, Luggya, Tony, Tugume, Liliane, Abassi, Mahsa, Birkenkamp, Kate, Butler, Elissa K., Fujita, A. Wendy, Halupnick, Ryan, Strain, Anna K., Vedula, Priya, Rajasingham, Radha, Kambugu, Andrew, Bohjanen, Paul R. · 2015 · Antimicrobial Agents and Chemotherapy
Cited by 191

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Cryptococcal antigen screening is recommended among people living with AIDS when entering HIV care with a CD4 count of <100 cells/μl, and preemptive fluconazole monotherapy treatment is recommended for those with subclinical cryptococcal antigenemia. Yet, knowledge is limited of current antimicrobial resistance in Africa. We examined antifungal drug susceptibility in 198 clinical isolates collected from Kampala, Uganda, between 2010 and 2014 using the CLSI broth microdilution assay. In comparison with two previous studies from 1998 to 1999 that reported an MIC 50 of 4 μg/ml and an MIC 90 of 8 μg/ml prior to widespread human fluconazole and agricultural azole fungicide usage, we report an upward shift in the fluconazole MIC 50 to 8 μg/ml and an MIC 90 value of 32 μg/ml, with 31% of isolates with a fluconazole MIC of ≥16 μg/ml. We observed an amphotericin B MIC 50 of 0.5 μg/ml and an MIC 90 of 1 μg/ml, of which 99.5% of isolates (197 of 198 isolates) were still susceptible. No correlation between MIC and clinical outcome was observed in the context of amphotericin B and fluconazole combination induction therapy. We also analyzed Cryptococcus susceptibility to sertraline, with an MIC 50 of 4 μg/ml, suggesting that sertraline is a promising oral, low-cost, available, novel medication and a possible alternative to fluconazole. Although the CLSI broth microdilution assay is ideal to standardize results, limit human bias, and increase assay capacity, such assays are often inaccessible in low-income countries. Thus, we also developed and validated an assay that could easily be implemented in a resource-limited setting, with similar susceptibility results ( P = 0.52).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1128/aac.01299-15

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 191

Metadata

Authors
Smith, K. D., Achan, B., Hullsiek, K. H., McDonald, T. R., Okagaki, L. H., Alhadab, A. A., Akampurira, A., Rhein, J. R., Meya, D. B., Boulware, D. R., Nielsen, K., Musubire, A., Nabeta, H. W., Williams, D. A., Morawski, B., Rolfes, M. A., Ndyetukira, J. F., Ahimbisibwe, C., Kugonza, F., Sadiq, A., Dyal, J., Neborak, J. M., King, A. M., Yueh, N., Velamakanni, S. S., Namudde, A., Kandole, T. K., Eva Laker, J. K., Luggya, T., Tugume, L., Abassi, M., Birkenkamp, K., Butler, E. K., Fujita, A. W., Halupnick, R., Strain, A. K., Vedula, P., Rajasingham, R., Kambugu, A., & Bohjanen, P. R.
Venue
Antimicrobial Agents and Chemotherapy
Published
2015-12
Volume
59
Issue
12
Pages
7197-7204
ISSN
  • 0066-4804 (ISSN-L)
  • 1098-6596
OpenAlex
W2337544181
Cited by
191
References
7
FWCI
11.01
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.